Dr Neil Walker Statistician, Oxford Biomedical Research Centre & North-51
Abstract
Pharmacotherapy is an important aid to smoking cessation. In the UK, three treatments are currently offered: Champix, Zyban and Nicotine Replacement Therapy (NRT).
Data from 89740 contacts using Stop Smoking services from 10 different Primary Care Trusts within the UK over the period 2002-2015 were analysed with regard to the association between prescribed pharmacotreatment and 4-week Russell standardised smoking quit rates. These effects were assessed using a logistic regression model also incorporating the effect of age, sex and the type of service used by the patient (group session participation, one-on-one with adviser etc). Further to the main effects, the 2-way interactions between treatment used and each of the other variables fitted were assessed. Preliminary results from analyses of these data indicate the most effective treatment in terms of overall quit rates was Champix (β=+0.11, p=0.004). In terms of interactions, significant differences in quit rates were observed with respect to NRT and female quitters (β=-0.03, p=0.02), NRT and type of service used and between Champix and type of service used.
The results of these analyses will be presented in detail and implications for clinical strategy discussed, particularly with respect to identifying optimal treatments for specific subgroups of the population.
Source of funding: Quit 51 Stop Smoking Service and Oxford Biomedical Research Centre.
Declaration of interest: None of the authors have a conflict of interest with respect to the presented research.
